C12N 2760/16131
Uses of virus other than therapeutic or vaccine
Official title: Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N2760/16131 (Uses of virus other than therapeutic or vaccine) appears on 14 US grants and 18 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 18
- Assignees
- 8
- Inventors
- 32
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 2 | 1 |
| 2019 | 0 | 1 |
| 2020 | 2 | 2 |
| 2021 | 2 | 2 |
| 2022 | 1 | 4 |
| 2023 | 3 | 1 |
| 2024 | 2 | 2 |
| 2025 | 1 | 0 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Method of labelling viral particles comprising anionic lipids with fluorescently-labelled negatively-charged polynucleotides in the presence of polyvalent cations21 Apr 2026US 12,607,635 B2Oxford University Innovation Limited
- Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production23 Sep 2025US 12,419,947 B2Najit Technologies, Inc.
- Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process1 Oct 2024US 12,102,676 B2Najit Technologies, Inc.
- Fabric top for a convertible vehicle and convertible vehicle16 Jul 2024US 12,036,852 B2Bayerische Motoren Werke Aktiengesellschaft
- Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production19 Dec 2023US 11,844,832 B2Najit Technologies, Inc.
- Covid-19 and respiratory disease virus infection models using lung organoids3 Sep 2026US 2026/0259197 A1The Catholic University of Korea Industry-Academic Cooperation Foundation
- Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production15 Aug 2024US 2024/0269257 A1Najit Technologies, Inc.
- Compositions and methods for the genetic manipulation of the influenza virus14 Mar 2024US 2024/0084267 A1
- Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process2 Nov 2023US 2023/0346910 A1Najit Technologies, Inc.
- Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process4 Aug 2022US 2022/0241395 A1Najit Technologies, Inc.
Most cited
By later US patents
- Mutations that confer genetic stability to additional genes in influenza viruses23US 10,053,671 B2Wisconsin Alumni Research Foundation (WARF) · 2018
- Mutations that confer genetic stability to additional genes in influenza viruses16US 11,046,934 B2Wisconsin Alumni Research Foundation (WARF) · 2021
- Mutations that confer genetic stability to genes in influenza viruses13US 11,241,492 B2Wisconsin Alumni Research Foundation (WARF) · 2022
- Mutations that confer genetic stability to additional genes in influenza viruses4US 11,802,273 B2Wisconsin Alumni Research Foundation (WARF) · 2023
- Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production2US 10,744,198 B2Najit Technologies, Inc. · 2020